Lyssavirus
Vaccines and Antiviral Agents | SpotlightIdentification and Characterization of a Small-Molecule Rabies Virus Entry InhibitorRabies PEP depends on anti-RABV IgG, which is expensive and in limited supply in geographical areas with the highest disease burden. Replacing the IgG component with a cost-effective and shelf-stable small-molecule antiviral could address this unmet clinical need by expanding access to life-saving medication. This study has established a robust protocol for high-throughput anti-RABV drug screens and identified a chemically well-behaved...
- Genetic Diversity and EvolutionQuantifying Antigenic Relationships among the Lyssaviruses
- Structure and AssemblyStructure of the Nucleoprotein Binding Domain of Mokola Virus Phosphoprotein
- Virus-Cell InteractionsMitochondrial Dysfunction in Lyssavirus-Induced Apoptosis
- Genetic Diversity and EvolutionPhylogeography, Population Dynamics, and Molecular Evolution of European Bat Lyssaviruses